Amphastar P (AMPH) - Total Liabilities
Based on the latest financial reports, Amphastar P (AMPH) has total liabilities worth $874.77 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amphastar P - Total Liabilities Trend (2012–2025)
This chart illustrates how Amphastar P's total liabilities have evolved over time, based on quarterly financial data. See Amphastar P current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Amphastar P Competitors by Total Liabilities
The table below lists competitors of Amphastar P ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Building Material
SHG:603060
|
China | CN¥3.08 Billion |
|
Yatharth Hospital & Trauma Care Services Limited
NSE:YATHARTH
|
India | Rs4.74 Billion |
|
Tigerair Taiwan Co. Ltd.
TW:6757
|
Taiwan | NT$20.36 Billion |
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
USA | $159.71 Million |
|
ALPHAMAB ONCOLO.DL-000002
F:3NK
|
Germany | €386.17 Million |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
USA | $188.85 Million |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
Turkey | TL16.00 Billion |
|
Indus Holding AG
XETRA:INH
|
Germany | €1.24 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Amphastar P's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AMPH stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amphastar P's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amphastar P (2012–2025)
The table below shows the annual total liabilities of Amphastar P from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $840.49 Million | -0.55% |
| 2024-12-31 | $845.17 Million | -3.24% |
| 2023-12-31 | $873.49 Million | +309.46% |
| 2022-12-31 | $213.33 Million | -5.61% |
| 2021-12-31 | $226.01 Million | +23.83% |
| 2020-12-31 | $182.51 Million | +14.47% |
| 2019-12-31 | $159.44 Million | +6.86% |
| 2018-12-31 | $149.20 Million | +27.16% |
| 2017-12-31 | $117.34 Million | +19.14% |
| 2016-12-31 | $98.48 Million | +4.08% |
| 2015-12-31 | $94.63 Million | -11.98% |
| 2014-12-31 | $107.51 Million | +23.29% |
| 2013-12-31 | $87.20 Million | +3.77% |
| 2012-12-31 | $84.04 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more